Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

XENE

Xenon Pharmaceuticals Inc.

Pharmaceutical Preparations · SIC 2834CIK 1582313Held by 9 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$8.0M
Net Income FY2025
$(346.0M)
EPS (Basic, as reported)
$-4.36
Net Margin FY2025
-4612.1%
ROE FY2025
-59.5%
Total Equity
$582.0M
Shares Out
97M
Business description

Xenon Pharmaceuticals Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2012–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 2 → 8 +16.7% CAGR
Fiscal yearFY2016FY2017FY2018FY2019⚑FY2020FY2021FY2022FY2023FY2024FY2025
Revenue20—732189008
Research & development(20)(26)(24)(39)(51)(75)(106)(168)(210)(301)
General & administrative(7)(7)(8)(11)(13)(22)(33)(47)(69)(80)
Total operating expenses(27)(33)(38)(50)(63)(97)(139)(214)(279)(381)
Operating income(25)(33)(38)(43)(31)(79)(129)(214)(279)(373)
Interest expense——(1)(1)0—————
Interest & investment income1012209284227
Other income (expense), net————204314128
Pre-tax income——(35)(42)(29)(79)(125)(183)(238)(345)
Income tax expense——000000(4)(1)
Net income(23)(31)(34)(42)(29)(79)(125)(182)(234)(346)
EPS — basic($1.48)($1.71)($1.63)—($0.81)($1.77)($2.06)($2.73)($3.01)($4.36)
EPS — diluted($1.48)($1.72)($1.63)—($0.81)($1.77)($2.06)($2.73)($3.01)($4.36)
Shares outstanding — basic (M)151819—354461677879
Shares outstanding — diluted (M)151819—354461677879

Showing the latest 10 of 14 fiscal years.

  • ⚑ Weighted-average shares changed ×1.84 between FY2018 and FY2020 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.